RENASCIENCE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 347 JPY | +0.58% |
|
+3.89% | -20.05% |
| Sales 2022 | 139M 878K 70.27M | Sales 2023 | 100M 631K 50.55M | Capitalization | 5.69B 35.95M 2.88B |
|---|---|---|---|---|---|
| Net income 2022 | -254M -1.6M -128M | Net income 2023 | -335M -2.11M -169M | EV / Sales 2022 | 25.1 x |
| Net cash position 2022 | 2.19B 13.81M 1.11B | Net cash position 2023 | 1.9B 12.01M 962M | EV / Sales 2023 | 37.9 x |
| P/E ratio 2022 |
-20
x | P/E ratio 2023 |
-17
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.58% | ||
| 1 week | +3.89% | ||
| Current month | -8.92% | ||
| 1 month | -7.47% | ||
| 3 months | -16.18% | ||
| 6 months | -27.10% | ||
| Current year | -20.05% |
1 week
334.00
347.00
1 month
328.00381.00
Current year
328.00440.00
1 year
328.00650.00
3 years
282.001 060.00
5 years
282.001 060.00
10 years
282.001 060.00
| Managers | Title | Age | Since |
|---|---|---|---|
Koji Naito
PSD | President | 65 | 31/12/18 |
Sho Kato
CTO | Chief Tech/Sci/R&D Officer | 35 | 30/04/18 |
Kazuhiro Ikeda
ADM | Chief Administrative Officer | 68 | 31/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yasuo Azuma
BRD | Director/Board Member | 76 | 31/03/19 |
Kazuhiro Ikeda
ADM | Chief Administrative Officer | 68 | 31/12/19 |
Toshio Miyata
CHM | Chairman | 63 | 31/03/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 347 | +0.58% | 9,100 |
| 25/04/24 | 345 | 0.00% | 5,900 |
| 24/04/24 | 345 | +0.58% | 10,700 |
| 23/04/24 | 343 | +1.48% | 16,000 |
| 22/04/24 | 338 | +1.20% | 57,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotes
Renascience Inc is mainly engaged in the development and sale of pharmaceuticals and medical devices. The company is engaged in the research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI) solutions) to solve problems in the medical field, in collaboration with physicians. The Company is engaged in the development of drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The Company is also engaged in the solve of other medical issues such as diseases of women and children, and COVID-19 infection.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.05% | 28.02M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4889 Stock
